CORTESI, LAURA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 15.299
AS - Asia 6.808
EU - Europa 5.711
SA - Sud America 1.027
Continente sconosciuto - Info sul continente non disponibili 433
AF - Africa 211
OC - Oceania 46
Totale 29.535
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.960
SG - Singapore 2.052
IT - Italia 1.599
CN - Cina 1.556
GB - Regno Unito 1.331
VN - Vietnam 801
HK - Hong Kong 792
BR - Brasile 765
DE - Germania 553
SE - Svezia 551
BD - Bangladesh 436
FI - Finlandia 304
RU - Federazione Russa 288
FR - Francia 247
UA - Ucraina 195
KR - Corea 177
TR - Turchia 168
CA - Canada 163
IN - India 160
ID - Indonesia 151
IE - Irlanda 117
BG - Bulgaria 96
MX - Messico 82
AR - Argentina 79
NL - Olanda 69
JP - Giappone 66
ZA - Sudafrica 64
IQ - Iraq 60
PL - Polonia 55
PK - Pakistan 48
BE - Belgio 44
EC - Ecuador 43
AU - Australia 42
MY - Malesia 42
AE - Emirati Arabi Uniti 41
AT - Austria 41
ES - Italia 38
SA - Arabia Saudita 38
MA - Marocco 37
CO - Colombia 36
VE - Venezuela 29
PH - Filippine 28
UZ - Uzbekistan 27
CL - Cile 26
LT - Lituania 26
EG - Egitto 22
PY - Paraguay 22
IR - Iran 19
KE - Kenya 19
CH - Svizzera 17
RO - Romania 16
TH - Thailandia 16
TN - Tunisia 16
JO - Giordania 15
NP - Nepal 15
GR - Grecia 14
SI - Slovenia 14
CR - Costa Rica 13
JM - Giamaica 13
TW - Taiwan 13
AZ - Azerbaigian 12
CZ - Repubblica Ceca 12
BZ - Belize 11
DZ - Algeria 11
IL - Israele 11
RS - Serbia 11
PE - Perù 10
SY - Repubblica araba siriana 10
DO - Repubblica Dominicana 9
HU - Ungheria 9
NO - Norvegia 9
PA - Panama 9
AL - Albania 8
BO - Bolivia 8
LV - Lettonia 8
TT - Trinidad e Tobago 8
GE - Georgia 7
UY - Uruguay 7
BY - Bielorussia 6
HN - Honduras 6
LB - Libano 6
OM - Oman 6
PT - Portogallo 6
SC - Seychelles 6
GT - Guatemala 5
KZ - Kazakistan 5
NI - Nicaragua 5
PS - Palestinian Territory 5
SV - El Salvador 5
AO - Angola 4
BB - Barbados 4
DK - Danimarca 4
EE - Estonia 4
ET - Etiopia 4
EU - Europa 4
HR - Croazia 4
KG - Kirghizistan 4
MD - Moldavia 4
MK - Macedonia 4
SN - Senegal 4
Totale 29.042
Salva come PNG Salva come JPEG
Città #
Ashburn 1.763
Fairfield 1.371
Santa Clara 1.287
Singapore 1.223
San Jose 799
Hong Kong 772
Woodbridge 747
Southend 735
Chandler 708
Houston 602
Seattle 550
Council Bluffs 503
Cambridge 488
Wilmington 440
Hefei 436
Beijing 327
Nyköping 317
Ann Arbor 307
Dearborn 301
Los Angeles 292
London 287
Jacksonville 286
New York 246
Ho Chi Minh City 244
Helsinki 221
Chicago 215
Milan 199
Hanoi 183
Modena 167
Seoul 161
The Dalles 154
Dallas 146
San Diego 135
Jakarta 118
Dublin 114
Lauterbourg 113
Princeton 100
Sofia 93
Izmir 89
Salt Lake City 89
Moscow 82
Munich 80
Buffalo 79
Bologna 71
Rome 71
Boardman 69
Eugene 68
São Paulo 67
Shanghai 66
Bremen 63
Orem 61
Tokyo 54
Frankfurt am Main 53
Columbus 48
Phoenix 45
Elk Grove Village 42
Dong Ket 39
Montreal 39
Brooklyn 38
Haiphong 38
Warsaw 37
Atlanta 36
Miano 36
Redwood City 34
Da Nang 32
Toronto 32
Florence 31
Chennai 30
Brussels 29
Johannesburg 29
Mexico City 29
Falls Church 28
Fremont 27
Miami 27
Denver 26
Belo Horizonte 25
Turku 25
Las Vegas 24
Reading 24
Tampa 24
Vienna 23
Amsterdam 22
Des Moines 22
Reggio Emilia 22
Sterling 22
Stockholm 22
Nuremberg 21
Philadelphia 21
Guangzhou 20
Rio de Janeiro 20
Tashkent 20
Baghdad 19
Kent 19
Naples 19
Ottawa 19
Brasília 18
Manchester 18
Norwalk 18
Parma 18
Portsmouth 18
Totale 19.487
Salva come PNG Salva come JPEG
Nome #
The italian multi-center project on evaluation of MRI and other imaging modalities in early detection of breast cancer in subjects at high genetic risk 575
A rapid genetic counselling and testing in newly diagnosed breast cancer is associated with high rate of risk-reducing mastectomy in BRCA1/2-positive italian women 485
Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going 403
Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status. 398
Prognosis and treatment of micrometastatic breast cancer sentinel lymph node: a population-based study. 393
Penetrances of breast and ovarian cancer in a large series of families tested for BRCA1/2 mutations 392
Identification of protein clusters predictive of response to chemotherapy in breast cancer patients 391
Protein expression patterns associated with advanced stage ovarian cancer 377
Elongation factor 1 alpha interacts with phospho-Akt in breast cancer cells and regulates their proliferation, survival and motility 370
Breast cancer screening in women at increased risk according to different family histories: an update of the Modena Study Group experience 366
Genomic alterations at the basis of treatment resistance in metastatic breast cancer: Clinical applications 366
Hereditary pancreatic cancer: A retrospective single-center study of 5143 Italian families with history of BRCA-related malignancies 365
Collective evidence supports neutrality of BRCA1 V1687I, a novel sequence variant in the conserved THV motif of the first BRCT repeat 360
A novel deletion of BRCA1 gene that eliminates the ATG initiation codon without affecting the promoter region 357
Double heterozygosity for BRCA1 and hMLH1 gene mutations in a 46-year-old woman with five primary tumors 354
Italian family with two independent mutations:3358T/A in BRCA1 and 8756delA in BRCA2 genes. 352
Ovarian cancer: can proteomics give new insights for therapy and diagnosis? 343
Molecular mechanisms of PARP inhibitors In BRCA-related ovarian cancer 339
Favourable ten-year overall survival in a Caucasian population with high probability of hereditary breast cancer. 329
Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients. 325
CHIRURGIA PROFILATTICA DELLA MAMMELLA NELLE PAZIENTI PORTATRICI DI MUTAZIONE DEL GENE BRCA 1/2. PERCORSO DIAGNOSTICO-TERAPEUTICO. 318
Prophylactic Surgery to Reduce the Risk of Developing Breast Cancer: Issues and Clinical Implications 309
MRI in high risk women: benefits and problems 307
Risk of second primary malignancy in breast cancer survivors: A nested population-based case-control study 306
Combined Hormonal Contraceptive Use and Risk of Breast Cancer in a Population of Women With a Family History 302
Identification of families with hereditary breast and ovarian cancer for clinical and mammographic surveillance: the Modena Study Group proposal 299
Hereditary Ovarian Cancer: Not Only BRCA 1 and 2 Genes 299
Usefulness and limitations of comprehensive characterization of mRNA splicing profiles in the definition of the clinical relevance of BRCA1/2 variants of uncertain significance 298
An oncologist-based model of cancer genetic counselling for hereditary breast and ovarian cancer 296
MRI before initial surgery outside of clinical trials: the real world! 294
Tumor size, node status, grading, HER2 and estrogen receptor status still retain a strong value in patients with operable breast cancer diagnosed in recent years. 291
Evaluation of Transvaginal Ultrasound plus CA-125 Measurement and Prophylactic Salpingo-Oophorectomy in Women at Different Risk Levels of Ovarian Cancer: The Modena Study Group Cohort Study 291
Clinicopathologic Profile of Breast Cancer in Germline ATM and CHEK2 Mutation Carriers 291
Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat? 288
Reproductive risk factors in women with family history of breast cancer attending an Italian Family Cancer Clinic 287
FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor 285
Multicenter comparative multimodality surveillance of women at genetic-familial risk for breast cancer (HIBCRIT study): interim results. 284
Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy 283
The Association between Endometriomas and Ovarian Cancer: Preventive Effect of Inhibiting Ovulation and Menstruation during Reproductive Life 283
A case of skeletal and bone marrow metastases from breast cancer treated with eribulin mesylate 282
Different expressivity of BRCA1 and BRCA2: analysis of 179 Italian pedigrees with identified mutation 282
BRCA1 mutations and clinico-pathological features in a sample of italian women with early-onset breast cancer 281
Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era 280
Prognosis of screen-detected breast cancers: results of a population based study 274
Breast ultrasonography (BU) in the screening protocol for women at hereditary-familial risk of breast cancer: has the time come to rethink the role of BU according to different risk categories? 274
Distribution of second primari malignancies suggest a bidirectional effect between breast and endometrial cancer. A population-based study 272
Acceptability and adherence in a chemoprevention trial among women at increased risk for breast cancer attending the modena familial breast and ovarian cancer center (Italy) 269
Increased incidence of breast cancer in postmenopausal women with high body mass index at the modena screening program 268
Comparison between genotype and phenotype identifies a high-risk population carryingBRCA1 mutations 266
A regional population-based hereditary breast cancer screening tool in Italy: First 5-year results 261
Hereditary risk of breast cancer: not only brca 254
STRATEGIES TO PREDICT TREATMENT RESPONSE AND SELECT THERAPIES IN METASTATIC BREAST CANCER PATIENTS USING A NEXT GENERATION SEQUENCING MULTI-GENE PANEL 253
Clinical and Pathological Features of Breast Cancer in Systemic Sclerosis: Results from the Sclero-Breast Study 253
Comment on "Cancer genetic counselling' by P.!Mandich et al. (Ann Oncol 2005; 16: 171) 252
The impact of reproductive life on breast cancer risk in women with family history or BRCA mutation 251
Outcome evaluation in pre-trastuzumab era between different breast cancer phenotypes: a population-based study on italian women 246
Characterization of new ATM deletion associated with hereditary breast cancer 245
Twenty-years experience with de novo metastatic breast cancer 243
Chemoprevention strategies for high risk women 243
Spatial Distribution of Immune Cells Drives Resistance to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer 241
Prediction of breast and prostate cancer risks in male BRCA1 and BRCA2 mutation carriers using polygenic risk scores 241
Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification 241
Chemoprevention strategies in hereditary breast and ovarian cancer syndromes 239
BRCA mutations among triple negative breast cancer without family history of breast and ovarian cancer: The Modena family cancer clinic experience 237
Male Bilateral Risk-Reducing Mastectomy: Report of a Case 234
Indications for breast magnetic resonance imaging. Consensus Document "Attualità in Senologia", Florence 2007 232
Usefulness of breast MRI in a patient with genetic risk 229
Radiological screening programs for women at high risk of developing breast cancer 229
Evaluation of widely used models for predicting BRCA1 and BRCA2 mutations 228
Automated capture-based NGS workflow: one thousand patients experience in a clinical routine framework 228
Breast ultrasound in high-risk women 221
Prevalence of BRCA1 genomic rearrangements in a large cohort of Italian breast and breast/ovarian cancer families without detectable BRCA1 and BRCA2 point mutations 221
Association of genomic domains in BRCA1 and BRCA2 with prostate cancer risk and aggressiveness 218
BRCA mutation carriers' perceptions on postmenopausal hormone therapy: An Italian study 217
Satisfaction with prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers is very high and little dependent on the participants' characteristics at surgery: a prospective study 216
Exceptional response to lurbinectedin and irinotecan in BRCA-mutated platinum-resistant ovarian cancer patient: a case report 207
Changes in breast cancer incidence and stage distribution in Modena, Italy: the effect of mammographic screening program. 202
Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies 200
Molecular Pathways of Breast Cancer in Systemic Sclerosis: Exploratory Immunohistochemical Analysis from the Sclero-Breast Study 200
The reduction of CA 125 serum levels in BRCA 1/2 mutation carriers after risk-reducing salpingo-oophorectomy is only partially associated with surgery: A prospective cohort, other biomarker controlled, study 198
Management of PALB2-associated breast cancer: A literature review and case report 194
Thromboembolism and Adjuvant Endocrine Therapy (AET) in Hormone Receptor-Positive Early Breast Cancer (EBC): Did Treatment Evolution Change Incidence of the Adverse Event? A Meta-Analysis 194
Multicenter surveillance of women at high genetic breast cancer risk using mammography, ultrasonography, and contrast-enhanced magnetic resonance imaging (the high breast cancer risk italian 1 study): final results. 194
Obesity in Postmenopausal Breast Cancer Patients: It Is Time to Improve Actions for a Healthier Lifestyle. The Results of a Comparison Between Two Italian Regions With Different “Presumed” Lifestyles 194
Personalized Systemic Therapies in Hereditary Cancer Syndromes 192
Adjuvant Endocrine Therapy in Premenopausal Women With Hormone Receptor-Positive Early-Stage Breast Cancer: Risk Stratification in a Real-World Setting 191
Constitutional Mosaicism: A Critical Issue in the Definition of BRCA-Inherited Cancer Risk 189
Primary fallopian tube carcinoma (PFTC) in a BRIP-1 mutation carrier: the first case report 189
The challenging screen detection of ovarian cancer in BRCA mutation carriers adhering to a 6-month follow-up program: results from a 6-years surveillance 174
DCE-MRI Radiomic analysis in triple negative ductal invasive breast cancer. Comparison between BRCA and not BRCA mutated patients: Preliminary results 173
BRCA mutation rate and characteristics of prostate tumor in breast and ovarian cancer families: analysis of 6,591 Italian pedigrees 171
Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores 171
Parp-inhibitors in the therapeutic landscape of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants: An Italian consensus paper and critical review 160
Automation of a capture-based NGS workflow: one thousand patients experience in a diagnostic clinical routine framework 157
Breast cancer screening of mutation carriers in the era of COVID-19 pandemic 157
The spectrum of fancm protein truncating variants in European breast cancer cases 155
A phase II study of pembrolizumab plus carboplatin in BRCA-related metastatic breast cancer (PEMBRACA) 154
Detection of germline variants in 450 breast/ovarian cancer families with a multi‐gene panel including coding and regulatory regions 151
Prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers: what is going on in a region of northern Italy? 146
Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer. 145
Totale 26.630
Salva come PNG Salva come JPEG
Categoria #
all - tutte 121.435
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 121.435
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.038 139 180 238 90 55 129 117 108 229 165 368 220
2022/20232.135 263 280 137 198 242 257 41 185 332 26 81 93
2023/20241.480 89 77 104 141 239 128 179 178 41 45 78 181
2024/20254.955 146 40 110 287 913 718 445 290 554 210 532 710
2025/202611.047 715 341 766 1.058 1.440 634 1.128 491 1.006 997 1.572 899
2026/2027656 656 0 0 0 0 0 0 0 0 0 0 0
Totale 29.535